Subscribe: HSMN NewsFeed
Preview: HSMN NewsFeed

HSMN NewsFeed

Healthcare Sales & Marketing Network NewsFeed

Last Build Date: Fri, 22 Sep 2017 03:54:56 CST


ManaMed Inc. Introduces PlasmaFlow, The World's First FDA-Approved Digital and Tubeless Deep Vein Thrombosis Prevention Device

Thu, 21 Sep 2017 15:27:18 GMT

PlasmaFlow Is Deep Vein Thrombosis (DVT) Prevention Made Simple SANTA ANA, Calif., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- The company's historical first FDA-approved portable and tubeless DVT prevention device is now available to m...
Devices, Product Launch
ManaMed, PlasmaFlow, Deep Vein Thrombosis

Paragon 28(R) launches 5th metatarsal fracture specific plating system, expanding the Baby Gorilla(TM) Mini Plating System offering

Thu, 21 Sep 2017 15:23:00 GMT

ENGLEWOOD, Colo., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Since its inception, Paragon 28 has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28 has l...
Devices, Orthopaedic, Product Launch
Paragon 28, Baby Gorilla, 5th Metatarsal, Plating System, foot and ankle surgery

FDA Releases Cefaly(R) for Acute Treatment of Migraine Attacks

Thu, 21 Sep 2017 13:21:15 GMT

NEW YORK, Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- CEFALY Technology announces today that on Friday, September 15th, the U.S. Food and Drug Administration (FDA) released the use of a new Cefaly® medical device for the acute treatmen...
Devices, Neurology, FDA
CEFALY Technology, trigeminal nerve stimulation, e-TNS, migraine

Varian Announces Penn Medicine Treats World's First Patient on Halcyon System

Thu, 21 Sep 2017 13:15:40 GMT

PALO ALTO, Calif., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced a patient at Penn Medicine, with head & neck cancer, became the first person in the world to be treated on Varian's Halcyon™ ...
Devices, Oncology
Varian Medical Systems, Halcyon System, IMRT, radiotherapy

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

Thu, 21 Sep 2017 12:55:35 GMT

First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base...
Biopharmaceuticals, Oncology, Regulatory
Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma

DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development

Wed, 20 Sep 2017 15:25:51 GMT

CUPERTINO, Calif., Sept. 20, 2017 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development. Dr. Theeuwes joins DURECT from Joh...
Biopharmaceuticals, Personnel
DURECT, Epigenetic Regulator, nonalcoholic steatohepatitis

Arvinas Appoints Dr. John Houston as President and Chief Executive Officer

Wed, 20 Sep 2017 15:23:51 GMT

NEW HAVEN, Conn., Sept. 20, 2017 -- (Healthcare Sales & Marketing Network) -- Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced the appointment of John Houston, Ph.D., as president and...
Biopharmaceuticals, Personnel
Arvinas, PROteolysis TArgeting Chimeras

Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis

Wed, 20 Sep 2017 15:21:59 GMT

Dr. Athena Countouriotis joins Trovagene's Board of Directors, bringing significant experience in oncology clinical development and orphan indications SAN DIEGO, Sept. 20, 2017 -- (Healthcare Sales & Marketing Network) -- Trovagene, Inc. (NASDAQ: TROV...
Biopharmaceuticals, Oncology, Personnel
Trovagene, Precision Cancer Monitoring, circulating tumor DNA

AIVITA Biomedical Announces New Discovery with Applications to Regenerative Medicine, Skin Aging and Hair Growth

Tue, 19 Sep 2017 15:43:17 GMT

Company discovers new methods of capturing and using short-range intercellular signals to stimulate a healthy cell environment IRVINE, Calif., Sept. 19, 2017 -- (Healthcare Sales & Marketing Network) -- AIVITA Biomedical today announced the discovery o...
Biopharmaceuticals, Regenerative Medicine, Dermatology
AIVITA Biomedical, intercellular signaling, stem cell niche, stem cell

Organogenesis Names New Chief Commercial Officer and Chief Operating Officer

Tue, 19 Sep 2017 15:26:53 GMT

Senior Leadership Team Announced as Company Expands Commercial Operations, Product Portfolio CANTON, Mass., Sept. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Organogenesis Inc., a commercial leader in the field of regenerative medicine with a...
Devices, Regenerative Medicine, Wound Care, Personnel
Organogenesis, acellular biomaterials

Esteemed Researcher and Clinical Oncologist W. Michael Korn, M.D. Joins Caris Life Sciences as Chief Medical Officer

Tue, 19 Sep 2017 15:22:57 GMT

Executive Appointment Further Strengthens the Company's Position as a Precision Medicine Leader Translating Molecular Insights into Therapeutic Action IRVING, Texas, Sept. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, ...
Diagnostics, Personalized Medicine, Oncology, Personnel
Caris Life Sciences, Caris Molecular Intelligence, ADAPT Biotargeting System

Varian to Showcase Latest Technologies and Software for Advanced Cancer Care at ASTRO 2017

Tue, 19 Sep 2017 15:18:46 GMT

PALO ALTO, Calif., Sept. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced it will be demonstrating its new Halcyon™ platform for simplifying and enhancing virtually every aspect of image-guided volum...
Devices, Oncology
Varian Medical Systems, HyperArc, Halcyon, ProBeam, radiotherapy

ARKRAY launches ADAMS(TM) A1c HA-8180V System for hemoglobin A1c testing

Mon, 18 Sep 2017 15:14:23 GMT

EDINA, Minn., Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- U.S. ARKRAY, Inc. (ARKRAY) announces the launch of the ADAMS™ A1c HA-8180V System for hemoglobin A1c testing. The system obtained FDA 510(k) clearance as an aid in the diagnosis and...
Diagnostics, FDA, Product Launch
ARKRAY, A1c HA-8180V System, hemoglobin A1c

Recros Medica Appoints Thomas A. Albright as President and CEO

Mon, 18 Sep 2017 15:11:26 GMT

SAN DIEGO, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring, announced today that Thomas A. Albright has been named P...
Devices, Dermatology, Personnel
Recros Medica, Rotational Fractional Resection

Tetracore(R) Inc. Announces European Approval of the T-COR 8(TM) Portable Real-time PCR Thermocycler

Mon, 18 Sep 2017 15:07:49 GMT

The next generation molecular diagnostics platform introduces novel connectivity solution designed to bring testing closer to the patient ROCKVILLE, Md., Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Tetracore today announced that the T-CO...
Diagnostics, Regulatory
Tetracore, T-COR 8, real-time PCR

Urovant Sciences Appoints Keith A. Katkin as Chief Executive Officer

Mon, 18 Sep 2017 13:11:16 GMT

Former CEO of Avanir Pharmaceuticals joins Roivant family of companies Plans to initiate confirmatory Phase 3 program of vibegron by early 2018 BASEL, Switzerland, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Urovant Sciences, a globa...
Biopharmaceuticals, Urology, Personnel
Urovant Sciences, Vibegron

Halyard Health Announces New Data Supporting COOLIEF* Cooled RF for the Treatment of Chronic Osteoarthritis Knee Pain

Mon, 18 Sep 2017 13:03:37 GMT

Study finds COOLIEF* Cooled RF provides significantly greater and longer-lasting pain relief, improved physical function and higher patient satisfaction than intra-articular steroid injections (1) ALPHARETTA, Ga., Sept. 18, 2017 -- (Healthcare Sales & M...
Devices, Orthopaedic
Halyard Health, COOLIEF, Cooled Radiofrequency, osteoarthritis

Kaleido Biosciences Announces Appointment of Mike Bonney as CEO and Completion of Additional Fundraising

Mon, 18 Sep 2017 12:56:19 GMT

Mike Bonney, former CEO of Cubist Pharmaceuticals, to lead Kaleido through its next phase of growth $65 million in funds raised since its founding in 2015 Funds to advance Kaleido's robust pipeline of novel microbiome therapies BEDFORD, Mass., Sep...
Biopharmaceuticals, Personnel, Venture Capital
Kaleido Biosciences, microbiome

Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer

Mon, 18 Sep 2017 12:47:05 GMT

SAN DIEGO, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Abide Therapeutics, a developer of innovative pharmaceuticals, announced today the appointment of Sapna Srivastava, Ph.D., to the position of Chief Financial and Strategy Officer. Dr. ...
Biopharmaceuticals, Personnel
Abide Therapeutics, serine hydrolase

BioVentrix announces the 1st Revivent TC(TM) TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment at the University Heart Center Zurich in Switzerland

Mon, 18 Sep 2017 12:36:49 GMT

SAN RAMON, Calif., and ZURICH, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use of its closed-ch...
Devices, Interventional, Cardiology
BioVentrix, Revivent TC, TransCatheter, Ventricular Enhancement

Myriad Genetics Announces Positive Data Supporting New riskScore(TM) Test at the 36th Annual Conference of the National Society of Genetic Counselors

Fri, 15 Sep 2017 16:50:39 GMT

Validation of Residual Risk Score to Predict Breast Cancer Risk in Women without Hereditary Cancer Mutations Is Highly Statistically Significant SALT LAKE CITY, Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (NASDAQ:MY...
Diagnostics, Personalized Medicine, Oncology
Myriad Genetics, riskScore, breast cancer

NCCN Guidelines to Include Categories of Preference

Fri, 15 Sep 2017 16:46:03 GMT

NCCN categories of preference will provide guidance on which recommendations within the NCCN Guidelines are optimal, while providing a range of recommendations to accommodate a variety of clinical circumstances FORT WASHINGTON, Pa., Sept. 15, 2017 -- (H...
Biopharmaceuticals, Devices, Oncology
National Comprehensive Cancer Network, NCCN

Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

Fri, 15 Sep 2017 16:41:35 GMT

Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23 FOR MEDICAL AND TRADE MEDIA ONLY BEERSE, Belgium, Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Janssen-Cilag International NV annou...
Biopharmaceuticals, Dermatology, Regulatory
Janssen-Cilag, Janssen, guselkumab, psoriasis

SCA Pharmaceuticals Appoints Milton Boyer as Chief Executive Officer

Fri, 15 Sep 2017 16:37:38 GMT

Boyer Brings More Than 25 Years of Experience in the Chemical and Pharmaceutical Industry LITTLE ROCK, Ark., Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- SCA Pharmaceuticals (SCA), a leading sterile outsourcing facility specializing in p...
Biopharmaceuticals, Personnel
SCA Pharmaceuticals

New eShunt System Presented at the American Academy of Neurological Surgery Annual meeting in Santa Barbara, CA

Fri, 15 Sep 2017 13:02:52 GMT

Early in vivo testing results show promise in treating communicating hydrocephalus BOSTON, Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- CereVasc, LLC, a company focused on improving the care of patients with communicating hydrocephalus a...
Devices, Neurosurgery
CereVasc , eShunt System, hydrocephalus

Neovii Pharmaceuticals AG Announces New CEO

Fri, 15 Sep 2017 12:57:14 GMT

RAPPERSWIL, Switzerland, September 15, 2017 -- (Healthcare Sales & Marketing Network) -- Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii Pharmaceuticals appointed Jue...
Biopharmaceuticals, Personnel
Neovii Pharmaceuticals

New indication for BRIVIACT(R) (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults

Fri, 15 Sep 2017 12:50:24 GMT

BRIVIACT® CV provides a new monotherapy treatment option for epilepsy patients 16 years of age and older with partial-onset (focal) seizures, which can be initiated at a therapeutic dose at day one Approval applies a newly established regulatory pat...
Biopharmaceuticals, Neurology, FDA
UCB, BRIVIACT, brivaracetam, epilepsy